Business Context and Reporting Period
This Form 8-K was filed by Pacira Pharmaceuticals, Inc. on January 6, 2012, reporting an event that occurred on January 3, 2012. The filing concerns the termination of a material definitive agreement involving the Company's wholly owned subsidiary, Pacira Pharmaceuticals, Inc. (PPI-CA), and EKR Therapeutics, Inc. (EKR).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the legal status of a strategic agreement rather than financial performance data.
Material Changes
On January 3, 2012, EKR Therapeutics, Inc. delivered a notice of termination to PPI-CA regarding two agreements dated October 15, 2009:
- The Amended and Restated Strategic Licensing, Distribution and Marketing Agreement.
- The Amended and Restated Supply Agreement.
Under these agreements, PPI-CA manufactured and supplied the product DepoDur to EKR, which held exclusive distribution rights in North, South, and Central America. The termination of the License Agreement is effective 180 days from the notice date, though EKR has requested a shorter notice period. The Supply Agreement will terminate concurrently with the License Agreement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a detailed risk factor analysis beyond the immediate impact of the agreement termination. The primary contingency noted is the potential for the termination to occur sooner than the standard 180-day notice period if EKR's request for a shorter period is granted.
Investor Verification Checklist
- Confirm the final effective date of the termination, specifically whether EKR's request for a notice period shorter than 180 days was accepted.
- Assess the financial impact of losing exclusive distribution rights for DepoDur in the Americas.
- Review subsequent filings for details on the Company's strategy to replace the terminated distribution channel.
- Verify if any litigation or dispute resolution proceedings have been initiated regarding the termination.